Precision medicine may help doctors determine the best treatment options for children with rare, aggressive, and advanced cancer. Information from a patient's entire genome helped personalize treatment options for children with cancer, according to a new study.
Researchers developed a way to personalize treatments for aggressive bladder cancer. Taking bladder tumors from individual patients, identifying actionable mutations, and grafting the tumors into mice, researchers were able to simultaneously test multiple therapies in the tumor models.
Organ transplant recipients are twice as likely to develop melanoma as people who do not undergo a transplant, and are three times more likely to die of the dangerous skin cancer, new research suggests.
Cancer researchers have identified a molecule linked to the survival of anaplastic thyroid carcinoma (ATC), a lethal tumor with no current effective therapies.
Working with cells taken from children with a rare form of brain cancer, scientists have identified a genetic pathway that may spur cancer cell growth and resistance to anticancer treatment.
In treatment for metastatic breast cancer, eribulin is effective as a first-, second-, or third-line chemotherapy regimen.
New study helps explain why pancreatic cancer is so lethal, with less than one-third of patients surviving even early stage disease.
Survival rates for patients who relapse in their battle with acute myeloid leukemia may benefit from therapies that combine an existing agent, cytarabine, with a newer compound, vosaroxin.
For the first time, researchers have found that exposure to radioactive iodine is associated with more aggressive forms of thyroid cancer, according to a careful study of over a thousand individuals.
A new comprehensive analysis of thyroid cancer from The Cancer Genome Atlas (TCGA) Research Network has identified markers of aggressive tumors, which could allow for improved targeted therapy.
Prostate cancer treatment controversy continues as study finds watchful waiting not enough for some menSeptember 26, 2014
An active controversy among oncologists concerns watchful waiting versus more active treatment for prostate cancer.
Researchers in Australia examined patient and tumor characteristics of melanomas for higher mitotic rates (a marker of tumor cell growth) in an effort to increase early detection.
New research raises the prospect that some cancer patients with aggressive tumors may benefit from a class of anti-inflammatory drugs currently used to treat rheumatoid arthritis.
An international team of scientists have discovered a faulty process in certain bladder cancers that could point to new ways to treat patients with an aggressive form of the disease.
Scientists have shown how a lung cancer patient's blood sample could be used to monitor and predict their response to treatment, which may pave the way for personalized medicine for the disease.
Vitamin D deficiency was an indicator of aggressive prostate cancer and spread of the disease in men who underwent their first prostate biopsy because of abnormal PSA test and/or DRE results.
The presence of chronic inflammation in benign prostate tissue was associated with high-grade, or aggressive, prostate cancer.
Severe vitamin D deficiency linked with higher grade and stage of prostate tumors, according to research.
A new type of strategy has been proposed to tackle an aggressive subtype of ovarian cancer by using a nanoscale drug-delivery system designed to target specific cancer cells.
A new study examined how a genetic mutation in untreated patients is linked to aggressive prostate cancer later in life.
Researchers have discovered why some of the most aggressive and fatal breast cancer cells are resistant to chemotherapy, and they are developing ways to overcome this resistance.
Findings from a study involving thousands of postmenopausal women suggest that women who develop invasive breast cancer may benefit from taking supplements that contain both multivitamins and minerals.
A little-used class of antidepressants appears potentially effective in combating a particularly deadly form of lung cancer, according to a new study.
Researchers have identified a gene signature that is expected to help predict which low-risk prostate tumors will become lethal.
A prominent protein activated by inflammation is the key instigator that converts glioblastoma multiforme cells to their most aggressive, untreatable form and promotes resistance to radiation therapy.
In a small study, most patients given low doses of azacitidine prior to standard chemotherapy for diffuse large B-cell lymphoma (DLBCL) remained cancer-free for up to 28 months.
The proportion of men with advanced-stage prostate tumors at diagnosis has dropped dramatically since the widespread implementation of PSA screening, but the proportion of men with aggressive cancers at diagnosis has not changed substantially.
The addition of BH3 mimetics to standard tamoxifen treatment improved the effectiveness of hormone therapy in luminal B cancers, an aggressive subtype of ER-positive breast cancer.
African American men with very-low-risk prostate cancer, and who meet criteria for active surveillance, but undergo immediate surgery are much more likely than men of other races to actually have aggressive disease.
A method has been developed to identify aggressive prostate cancers that require immediate therapy.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|